Radiaction Medical, an Israeli medtech startup developing radiation protection technology for medical staff during interventional procedures, raised $12.6 million in Series C2 funding led by U.S. private equity fund InnovaHealth Partners
Radiation is energy that travels in waves or particles. It can come from natural sources, such as the sun and the earth, or from man-made sources, such as nuclear power plants and medical imaging devices.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
The amount of radiation exposure that is harmful depends on the type of radiation, the dose, and how the person is exposed.
Radiation exposure within the catheterization lab presents significant occupational health risks. Studies have shown an increased risk for brain tumors, breast cancer, cataracts, cognitive degradation, thyroid disease, fetal exposure, and orthopedic injuries when exposed to ionizing radiation. The need for advanced solutions is imperative.
Founded in 2014 by Amir Belson MD, Radiaction Medical boasts that it is revolutionizing radiation protection for interventional medical teams, focused on specialties that endure the highest exposure rates and serious health risks. In what it describes as a complete departure from current solutions that shield or clothe users to block radiation, the company created Radiaction, a plug-and-play addition to C-arm systems that dynamically and proactively blocks over 90% of scatter radiation at the source, offering head-to-toe protection for everyone in the room. Radiaction carries CE marking and FDA clearance and is currently marketed in North America and the European Union (EU).
The novel Radiaction system is the first and only advanced technology to proactively block radiation at the source, providing comprehensive, head-to-toe radiation protection to the entire interventional team while allowing unencumbered patient care, access, and service. Radiaction is clinically supported with extensive lab testing and real-world, peer-reviewed, published literature validating its performance in clinical settings.
Jonathan Yifat, Radiaction CEO, said, “This current financing round is a significant step forward, one that enables us to expand our reach further, lead with exceptional customer support, and provide this essential technology to protect those who care for patients.” He continues, “The addition of Christopher Barys is a tremendous asset to the strategic composition of our Board of Directors. Chris has a proven track record of market development and growth within the interventional space we aim to serve. He brings a keen eye for strategic opportunities and will help guide our company through its next stages of growth.”
